The present study is the first one that evaluated the relation between antiganglioside antibodies and IL-8 and CRP, based on their role in melanoma diagnosis, progression, and outcome [14, 46–49], in metabolic disorders [50, 51]. Here, CXCL8 is linked to metabolic disease.